Press Release|

SHL celebrates grand opening of its Liufu site in Taoyuan, Taiwan

Ribbon Cutting S

On November 5, SHL Group, a global leader in the design, development, and manufacturing of drug delivery devices, held the inauguration of its new Liufu site in Taoyuan City, Taiwan.

SHL’s largest facility to date, the Liufu site spans 63,000 m2 of modern office space and advanced manufacturing capacities. SHL has already installed five dozen brand new, fully electric injection molding machines and has further plans to expand to over 100 – promising high volume production of SHL Medical’s autoinjectors. The site also boasts a dozen cutting-edge, fully automated high-output assembly equipment. The facility was built to ensure not only optimal production but also ensure quality of SHL Medical’s line of drug delivery devices using advanced, high-accuracy testing and laboratory equipment.

A state-of-the-art building, the Liufu site is designed with energy-efficient features. Among these, heat generated from its fully electric molding machines can be repurposed for power-saving consumption. Also, the facility utilizes a centralized monitoring system to automatically manage energy consumption, ensuring efficient electricity usage.

The inauguration ceremony was attended by various professionals and government dignitaries. The Speaker of Taiwan’s Legislative Yuan, Su Jia-Chyuan and Vice Minister of Economic Affairs Wang Mei-Hua were all present to grace the celebration. Officials from the central as well as local Taoyuan government were welcomed by SHL Founder Roger Samuelsson and SHL Medical CEO Ulrich Faessler.

“With decades of industry experience and beyond, we move towards an unprecedented expansion of our people and facilities. Establishing the Liufu facility is part of our vision and commitment to advancing the production of our autoinjectors, which have helped redefine the patient experience of self-injection over the years,” said Ulrich Faessler, CEO of SHL Medical.

Celebrating 30 years of unparalleled leadership in the drug device industry, SHL welcomes the advent of digital technologies and the inherent advantages it brings to the future of healthcare. Strongly realizing the need to develop connected therapeutics – SHL, in collaboration with digital healthcare companies, will establish connected devices that will help improve the drug device experience of end users. Currently, SHL has also been active in supporting the development of a solar-powered water distribution system as part of its agenda to support clean water for sustainable food production.

SHL is ready to commence with the Liufu factory’s automated manufacturing operations.

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  ​

In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.​

For additional information, visit www.shl-medical.com

Media contact: info@shl-medical.com

Share:

Related News

SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors, and innovative specialty delivery systems has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM), a highly regarded contract development and manufacturing organization (CDMO) specializing in sterile injectable biologics and scalable pharmaceutical manufacturing solutions tailored to diverse client needs.